Innovate UK

Functional proteins and ingredients from pulses for use in plant-based foods and supplements.

Calla Lily Clinical Care is a women’s health-focused B-Corp that has created the proprietary Callavid® platform for intravaginal drug delivery. The company targets fertility and pregnancy with its innovative drug-device combination product aimed at preventing miscarriages and providing support during the luteal phase of In Vitro Fertilization (IVF). Additionally, Callavid® is designed to deliver live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic use and mitigating the spread of antimicrobial resistance. Other applications include hormone replacement therapy for menopause and the Lilyvid™ device, which facilitates advanced medical sample collection for biomarker-based diagnostics related to endometriosis and various other health conditions. The technology behind these devices has been recognized as a TIME Magazine Best Invention of the Year.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.